Published in Medicine and Law Weekly, August 25th, 2006
Additionally, two of the study's three planned interim safety analysis have already been conducted, the second recently. No safety concerns were raised by the data monitoring committee and continuation of the study was approved. Specifically, the rate of symptomatic bleedings, which is a major concern of treating physicians, has been below predefined levels.
The study explores the efficacy of Paion's drug candidate Desmoteplase in acute ischaemic stroke and was started in 2005 Forest Laboratories Inc. It is slated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.